LYFE Capital
LYFE Capital is a life science investment firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed LYFE Capital Information
Geographic Data
Address: Suite 1804, UNITED PLAZA
City: Shanghai
State: shanghai municipality
Zip: 200040
Country: CN
Financial Info
Stage:
Raised Last:
$0
Raised Total:$420M
Social
Linkedin
Crunchbase
Metrics
7,056,142Website Global Rank
625Website Monthly Traffic
Twitter Followers
Description
In our inaugural fund, we are only seeking biotechnology, pharmaceutical, medical device, diagnostic, healthcare service and digital health companies with an established product foundation but need a bit more capital to accelerate its growth in Greater China. During this critical time, we work closely with our portfolio companies and support their needs not only by providing capital but with market planning, talent acquisition, global expansion and global partnership support.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2021 | Zhenyi Yiliao | Series A | - |
| 1/2023 | Genepoint Biological Technology | Series D | 29.5M |
| 6/2021 | RecBio | Series C | 156.3M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2022 | Edgene Biot | Angel Round | - |
| 6/2022 | ProfoundBio | Series A | 0 |
| 4/2021 | Nucleix | Venture Round | 55M |
| 9/2014 | WinnTi Medical | Series A | 13M |
| 11/2017 | Baixing Pingan Yaofang | Venture Round | 30.3M |
| 3/2022 | Medilink Therapeutics | Series B | 70M |
| 8/2015 | Burning Rock Biotech | Series A | 23.5M |
| 10/2021 | Sciwind Biosciences | Series C | 0 |
| 11/2020 | Cytek Biosciences | Series D | 120M |
| 12/2020 | CANbridge Pharmaceuticals | Series E | 0 |
| 11/2020 | RecBio | Series B | 0 |
| 4/2022 | Shenji Bio | Series A | 47.1M |
| 5/2022 | Boyue Bio | Series A | 22.3M |
| 2/2021 | Cleveland Diagnostics | Series D | 17.4M |
| 4/2021 | Abogen Biosciences | Series B | 91.6M |
| 1/2022 | Zhenge Biotech | Series C | 100M |
| 7/2021 | neoX Biotech | Venture Round | - |
| 5/2022 | Starna Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 8/2019 | Just Medical | Series A | - |
| 9/2021 | HC Scientific | Series B | 31M |
| 8/2019 | HiFiBiO | Series C | 0 |
| 2/2021 | Sciwind Biosciences | Series B | 37M |
| 11/2021 | Edge Medical Robotics | Series C | 0 |
| 2/2021 | Exegenesis Bio | Series B | - |
| 2/2019 | Burning Rock Biotech | Series C | 125.5M |
| 3/2022 | Molecular Assemblies | Series B | 0 |
| 2/2022 | Genepoint Biological Technology | Series C | 0 |
| 5/2018 | Ansun BioPharma | Series A | 85M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 3/2021 | ImmuneOnco Biopharma | Series C | - |
| 6/2015 | Zhangkong Tangniaobing | Series A | 9.7M |
| 9/2018 | Aohua | Series D | 43.7M |
| 4/2022 | Elixir Clinical Research | Series A | 0 |
| 7/2021 | ProfoundBio | Series A | 0 |
| 12/2022 | Dieshi-DISC | Series A | 12.9M |
| 12/2016 | Burning Rock Biotech | Series B | 43.1M |
| 8/2020 | Shenqi Medical | Series C | 14.5M |
| 2/2021 | ABclonal | Series C | 0 |
| 1/2018 | Laviana Pharma | Series B | 15M |
| 3/2020 | Zhenge Biotech | Series A | 51M |
| 7/2022 | MobiDrop | Series A | 13.3M |
| 10/2020 | ImmuneOnco Biopharma | Series B | 25M |
| 4/2022 | Levostar | Seed Round | - |
| 5/2021 | Jianjia Robot | Series C | - |
| 5/2018 | HiFiBiO | Series B | 37.5M |
| 1/2021 | Edge Medical Robotics | Series B | 92.8M |
| 7/2022 | MobiDrop | Series A | 0 |
| 6/2022 | ProfoundBio | Series A | 0 |
| 5/2022 | Starna Therapeutics | Series A | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 5/2022 | Boyue Bio | Series A | 0 |
| 4/2022 | Elixir Clinical Research | Series A | 0 |
| 4/2022 | Shenji Bio | Series A | 0 |
| 3/2022 | Molecular Assemblies | Series B | 0 |
| 3/2022 | Medilink Therapeutics | Series B | 0 |
| 2/2022 | Genepoint Biological Technology | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
